Prior to the era of PARPi, index cases of ovarian cancer were selected for germline BRCA1/2 testing based on their risk of hereditary cancer, with age at diagnosis and family history used to determine risk [2,3,4]. This evidence concerns the gene BRCA1 and ovarian cancer.